Impact Of Metformin In Rectal Cancer Patients

Summary

Design: Prospective, randomized controlled clinical trial Setting: at Minia University Hospital and Minia Oncology Institute. Condition: Colorectal cancer. To be eligible for participation, patients must meet the following criteria: 1. Histologically confirmed diagnosis of rectal adenocarcinoma. 2. Age starting from 18 and older. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 4. Adequate organ function (renal, hepatic, and hematological) 5. Signed informed consent. Patients will be randomized into two groups: Group A: Patients will receive standard chemoradiotherapy(CRT). Group B: Patients will self-administer 1000mg of metformin twice daily by mouth: 1. beginning 1-2 weeks before standard CRT. 2. during standard CRT. 3. until 30 days after the end of standard CRT.

Timeline

Start

2024-05-01

Primary completion

2025-06-15

Completion

2025-07-15

Publications

• Awad OM, Saber MA, Ali Sholkamy NH, Abdel-Azeez AM, Sadek EM, Mady FM. Metformin enhances the pathological response in nondiabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: A randomized controlled trial. J Pharmacol Exp Ther. 2026 Jun 19;393(8):104970. doi: 10.1016/j.jpet.2026.104970. Online ahead of print.

Drugs

Indications